Leadership Overview
ElevateBio has 4 executives leading key functions including corporate strategy, operational scaling, financial management, and advanced technology development.
Focused on accelerating the next generation of genetic medicines, ElevateBio builds and operates a diverse portfolio of cell and gene therapy companies to transform patient outcomes through scientific innovation.
Focused on accelerating the next generation of genetic medicines, ElevateBio builds and operates a diverse portfolio of cell and gene therapy companies to transform patient outcomes through scientific innovation.
Leadership Roles at ElevateBio
Christopher Murphy - Chief Executive Officer & Board Member
Christopher Murphy, the Chief Executive Officer & Board Member at ElevateBio, directs the overarching corporate strategy and long-term vision for the entire portfolio of cell and gene therapy companies. Murphy manages high-level partnerships with leading scientists and inventors to ensure the rapid advancement of therapeutic candidates from concept to clinical application. By aligning board objectives with operational execution, the Chief Executive Officer & Board Member maintains a focus on sustainable growth and market leadership within the biotechnology sector. Christopher Murphy oversees the integration of various subsidiary entities, ensuring consistent adherence to the mission of creating transformative genetic medicines. This leadership role involves constant evaluation of the competitive landscape across North American markets to identify new opportunities for expansion. Through rigorous oversight of capital allocation and strategic planning, the Chief Executive Officer & Board Member secures the necessary resources to drive innovation and deliver significant value to stakeholders and patients alike.

Bhakti Bhargava - Chief Financial Officer
Bhakti Bhargava, the Chief Financial Officer at ElevateBio, directs the financial planning, reporting, and capital management strategies essential for sustaining a complex portfolio of cell and gene therapy companies. Bhargava oversees the allocation of investment funds to high-potential research projects, ensuring that financial resources align with the long-term goals of the organization. By managing investor relations and financial risk, the Chief Financial Officer provides the stability necessary for sustained innovation in the biotechnology space. Bhakti Bhargava evaluates the economic viability of new partnerships and potential acquisitions to expand the company's market footprint. This leadership role involves close collaboration with the Board to maintain fiscal discipline while pursuing aggressive growth targets. Through the implementation of robust financial controls and data-driven forecasting, the Chief Financial Officer supports the overall mission of delivering advanced genetic medicines. Bhargava ensures that the company remains well-positioned to navigate the capital-intensive nature of the life sciences industry while maximizing shareholder value.
Steve Falcone - Chief Operating Officer
Steve Falcone, the Chief Operating Officer at ElevateBio, manages the internal infrastructure and cross-functional workflows required to support a growing portfolio of biotechnology ventures. Falcone optimizes operational efficiency across all subsidiary companies, ensuring that research and development timelines remain on track for critical milestones. By streamlining internal processes, the Chief Operating Officer facilitates seamless collaboration between scientific teams and administrative departments. Steve Falcone monitors the performance of various operational units to maintain high standards of quality and compliance in gene therapy manufacturing. This role requires constant coordination with other C-suite leaders to align resource distribution with the broader corporate strategy. Falcone drives the implementation of scalable systems that allow the organization to adapt to the evolving demands of the global cell therapy market. Through meticulous management of daily operations, the Chief Operating Officer ensures that the company maintains a competitive edge while fostering an environment conducive to rapid scientific discovery and commercial success.

Michael Paglia - Chief Technology Officer, Elevatebio Basecamp
Michael Paglia, the Chief Technology Officer, Elevatebio Basecamp at ElevateBio, architects the technical infrastructure and manufacturing capabilities required to support the development of complex cell and gene therapies. Paglia leads the technological advancement of the Basecamp platform, ensuring that all portfolio companies have access to state-of-the-art tools and processes for therapeutic production. By overseeing the integration of cutting-edge laboratory technologies, the Chief Technology Officer, Elevatebio Basecamp drives the efficiency of the entire research-to-manufacturing pipeline. Michael Paglia manages the technical teams responsible for scaling production processes to meet clinical and commercial requirements. This role involves constant interaction with scientific inventors to translate novel concepts into scalable, high-quality manufacturing solutions. Through the continuous improvement of technical workflows, the Chief Technology Officer, Elevatebio Basecamp ensures that the organization remains at the forefront of biotechnology innovation. Paglia maintains a focus on technical excellence to accelerate the delivery of life-changing treatments to patients across global markets.
Explore Leadership Teams in Holding Companies & Conglomerates
Caldic is a leading provider of tailored solutions and market-ready ingredients across various sectors, including Life Sciences, Personal Care, and Biopharma. The company leverages deep technical expertise and a global supplier network to support innovation and help clients create market-leading products. With a commitment to sustainability and co-creation, Caldic delivers high-quality ingredients that meet the evolving demands of consumers. Their extensive services include custom blending, formulation support, and regulatory guidance, ensuring compliance and quality across all operations.
Company Leadership AV
AB
EM
KM
Hotel Equities is a full service, select service, boutique, independent, and lifestyle hotel management company. The company offers services including Third Party Management, Opportunity Zone Investing, Financing, Portfolio Acquisitions, and Development Services. The company was formed in 1989 and is headquartered in Atlanta, Georgia.
Company Leadership DR
JS

PT
Modon is an international holding company, headquartered in Abu Dhabi, United Arab Emirates, and listed on the Abu Dhabi Securities Exchange (ADX). We are at the forefront of urban innovation, creating iconic designs and experiences that continually surpass expectations. Our primary business sectors include real estate, hospitality, asset management, investments, events, and tourism. Our goal is to deliver long-term, sustainable value, laying the foundations for intelligent, connected living.
Company Leadership AK
IA
BO
MM
JM Family Enterprises, Inc. is a privately held, diversified automotive-focused company headquartered in Deerfield Beach, Florida. Founded in 1968 by Jim Moran, the company has grown from a Toyota distributor into a broad-based enterprise with operations spanning automotive distribution, retail, finance, insurance, logistics, and related services.
The company is best known for its role as a major distributor of Toyota vehicles and parts across the Southeast United States through its Southeast Toyota Distributors business. JM Family also operates automotive dealerships and provides financial products and services through Southeast Toyota Finance. Its portfolio includes additional businesses supporting vehicle logistics, insurance, technology, and automotive-related services.
Company Leadership SZ
CP